CervoMed (CRVO)

• Market cap: $78.5M
• 1 day: -3.41%
• 5 days: 1.46%
• 1 month: -0.98%
• 3 months: 302.67%
• 6 months: -35.65%
• Year to date: 306.28%
• 1 year: -62.70%
• 5 years: -63.98%
• 10 years: -99.72%
• Sector: Healthcare
• Industry: Biotechnology

About: CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

Employees: 15

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

30% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 10

6% less funds holding

Funds holding: 49 [Q3] → 46 (-3) [Q4]

19% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 16

24.48% less ownership

Funds ownership: 42.49% [Q3] → 18.01% (-24.48%) [Q4]

93% less capital invested

Capital invested by funds: $51.2M [Q3] → $3.46M (-$47.7M) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $10 10% upside
• Avg. target: $16 77% upside
• High target: $21 132% upside

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

D. Boral Capital Jason Kolbert 28% 1-year accuracy 107 / 376 met price target	10% upside $10	Buy Maintained	26 Mar 2025
Roth MKM Boobalan Pachaiyappan 40% 1-year accuracy 4 / 10 met price target	121% upside $20	Buy Maintained	18 Mar 2025
Canaccord Genuity Sumant Kulkarni 10% 1-year accuracy 3 / 30 met price target	132% upside $21	Buy Maintained	18 Mar 2025
Chardan Capital Daniil Gataulin 22% 1-year accuracy 11 / 50 met price target	55% upside $14	Buy Maintained	18 Mar 2025
Jones Trading Soumit Roy 15% 1-year accuracy 2 / 13 met price target	66% upside $15	Buy Upgraded	13 Mar 2025